Injectable Egg-Free Influenza Vaccine
DLA Troop Support · DLA TROOP SUPPORT
Capture briefs (a one-page, shareable copy of this page) are part of Pro. The CSV here holds the notice, its timeline and past awards.
Where this opportunity stands
Every notice posted under solicitation SPE2DP-24-R-0006 in this department, oldest first.
Next steps for this stage
Standard steps for the notice type; not advice about this buyer.
- Answer the notice: this is when the requirement can still be shaped.
- Contact the contracting officer named on the notice.
- Check who won similar work; they are the likely bidders.
What the notice says
The Defense Logistics Agency Troop Support is soliciting for the supply of Injectable Egg-Free Influenza Vaccine for the 2025-2026 flu season. Approximately 280,000 doses are included in this requirement. (Quantities may increase or decrease pending receipt of final Service requirements.)The vaccines shall be in the following presentations: prefilled syringes. The vaccine shall be FDA-approved for immunizing individuals 18 years and older. The formula for the 2025-2026 season shall be determined by the FDA�s Vaccines and Related Biological Products Advisory Committee. Other specification data … (show all)
is included in the solicitation. Successful contractor must have FDA Approval and the vaccine must be ACIP recommended. National Stock Numbers shall be established at time of award. An indefinite quantity contract is proposed. The quantity indicated is anannual estimate only. The guaranteed minimum will be 10% of the annual estimate, and a contract maximum will be established at 150% of theannual estimate. Ordered quantities shall be delivered to the Defense Depot New Cumberland, PA. The contractor shall be capable of delivering 40% of the order qty. by August 11, 2025, 25% by August 25, 2025, 25% by September 8, 2025, and the residual 10% by September 22, 2025 after receipt of the delivery order. The Delivery Schedule shall apply to the estimated annual quantity. This delivery schedule is the preferred delivery schedule. Other delivery schedules may be considered. Solicitation SPE2DP-24-R-0006 is expected to be issued on or around October 18, 2024 and can be found on the DLA Bid Board System (DIBBS) at https://www.dibbs.bsm.dla.mil and SAM.gov at https://www.sam.gov.
Who won similar work
18 award notices on SAM.gov in the last 24 months. Matched by: Same office (DLA TROOP SUPPORT), same product/service code (PSC) 6505.
Single-winner award sizes (16): middle half $4.0M to $15.0M, median $8.8M; range $1.8M to $133.2M.
| Winner | Awards | Value | Last |
|---|---|---|---|
| Golden State Medical Supply, Inc. | 8 | $184.6M | Oct 14, 2026 |
| AVKARE LLC | 2 | $13.7M | Sep 1, 2026 |
| SpecGx, LLC | 2 | $13.2M | Sep 9, 2026 |
| SANOFI PASTEUR INC. | 1 | $25.1M | Apr 25, 2025 |
| Exelan Pharmaceuticals Inc. | 1 | $24.1M | Jun 13, 2025 |
| Bayer HealthCare Pharmaceuticals Inc | 1 | $10.3M | Jun 3, 2026 |
| PURACAP LABORATORIES LLC | 1 | $6.4M | Jun 9, 2026 |
| PADAGIS SOURCING SOLUTIONS LLC | 1 | $3.2M | Jul 23, 2026 |
| RADHA PHARMACEUTICALS INC | 1 | – | Sep 14, 2026 |
Value counts new single-winner awards. "Shared" awards are multiple-award contracts that list every winner with the same total ceiling (same contract, or the same office, day and amount); that ceiling is not one company's win, so it is not added in. Contract modifications are not new awards and are not added in either (2 here). Revenue next to a ticker is the company's revenue over the latest 12 months in its SEC filings.
- Oct 14, 2026Golden State Medical Supply, Inc.$15.3MPravastatin SolicitationNo listed company matched (Materiality N/A)
- Oct 7, 2026GOLDEN STATE MEDICAL SUPPLY INC$4.3MQuetiapine Fumarate XR TabletsNo listed company matched (Materiality N/A)
- Sep 24, 2026GOLDEN STATE MEDICAL SUPPLY INC$17.6M (modification)Olopatadine HCL 0.1% Ophthalmic SolutionContract modification, not a new award (Materiality N/A)
- Sep 14, 2026RADHA PHARMACEUTICALS INC$23.3M (modification)Bupropion HCL ERContract modification, not a new award (Materiality N/A)
- Sep 9, 2026SpecGx, LLC$5.9MMethylphenidate HCL IRNo listed company matched (Materiality N/A)
- Sep 3, 2026GOLDEN STATE MEDICAL SUPPLY, INC.$2.4MSolifenacin AwardNo listed company matched (Materiality N/A)
- Sep 2, 2026SPECGX LLC$7.3MOxycodone HCL-Acetaminophen TabletsNo listed company matched (Materiality N/A)
- Sep 1, 2026AVKARE LLC$11.9MAnastrozole - AwardNo listed company matched (Materiality N/A)
- Jul 23, 2026PADAGIS SOURCING SOLUTIONS LLC$3.2MClindamycin Phosphate - Benzoyl Peroxide GelNo listed company matched (Materiality N/A)
- Jul 21, 2026GOLDEN STATE MEDICAL SUPPLY INC$12.1MTolterodine Tartrate ER 24HR CapsulesNo listed company matched (Materiality N/A)
Competitive landscape
For the 8 most frequent past winners above. Lobbying is matched by the company's exact name or exact ticker; agencies are as named on the filings.
- 0 of these past winners lobbied Defense Logistics Agency since 2024 (0 filings)
- 0 of their lobbyists list a past Defense Logistics Agency job
- No corporate PAC money from them to the overseeing committees since 2024
- 0 foreign-agent (FARA) registrations
Policy around it
Bills the past winners named while lobbying this agency's issues, rules from the department, and executive orders that name the agency, last 12 months.
- 0 bills named on the past winners' lobbying filings
- 32 rules from the department in the last 12 months
- 0 executive orders naming the agency in the last 12 months
Market
For past winners matched exactly to a listed company. Insider trades are open-market buys and sells (Form 4) in the last 90 days, shown as facts; our own study found insiders do not reliably buy ahead of awards. A sale marked 10b5-1 was made under a trading plan set up in advance.
- 0 of the past winners are listed companies
- 0 insider buys and 0 insider sells at them in the last 90 days
Sources: SAM.gov notices and award notices; Senate LDA lobbying filings; FEC filings; FARA; Federal Register; congress.gov; SEC Form 4. Every row above links to its record.
Companies are matched to tickers by exact name, including the subsidiaries a company lists in its SEC filings. A company we could not match shows no market rows; that is a miss, not a finding.